Roche's Genentech subsidiary is embarking on a $125 million project that will take Roche's investment in biologics production to over $1 billion and add 100 more jobs to the 500 Roche initially said its biologics expansion would create.
Roche handled hazardous chemicals at its now-shuttered facility in Nutley, NJ--and its neighbors say the company didn't do it properly.
To help healthcare providers more easily track drug shortages, the FDA has released a mobile app that will allow anyone to use a smartphone to look up current shortages and discontinuations as well as shortages that have been resolved.
Genentech begs to differ with a survey finding that its new distribution method is delaying treatment for some cancer patients. Hospitals may be complaining in press releases about the change to Herceptin, Rituxan and Avastin purchasing, but they're not reporting particular treatment problems to the company, Genentech says.
Top hospitals are still irate about Genentech's decision to move its best-selling cancer drugs to specialty distributors. And they're not giving up on persuading the company to change back.
After nearly a year off the shelves, GlaxoSmithKline's diet pill alli--recalled after reports of tampering--is back in most U.S. stores, and it's got some updates that should make any future tampering easier to spot.
Roche closed its Clifton, NJ, campus in 2013 and hopes to be free of the property this year. But some area residents want to slap the Swiss drugmaker with a lawsuit before it leaves town, concerned about whether the site has caused environmental issues over the years that will make it difficult for them to sell their homes.
SINGAPORE-- Hong Kong health facilities say a monthlong outbreak of H3N2 influenza has drained their supply of the drug they use for treatment, Roche's Tamiflu.
SINGAPORE-- One of the world's most prestigious medical journals called for India to abandon its current proposal to change the way it regulates drugs and come up with a new plan.
The summit meeting between President Barack Obama and India Prime Minister Narendra Modi resulted in no breakthroughs, such as on intellectual property, but did lead to about a dozen smaller agreements on various issues affecting the pharmaceutical industries.